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The p38 mitogen-activated protein kinase (MAPK) pathway plays an important role in cellular
responses to inflammatory stimuli and environmental stress. p38 regulated/activated protein
kinase (PRAK, also known as mitogen-activated protein kinase activated protein kinase 5 [MAP-
KAPK5]) functions downstream of p38 and p38 in mediating the signaling of the p38 pathway.
Immunostaining revealed that endogenous PRAK was predominantly localized in the cytoplasm.
Interestingly, ectopically expressed PRAK was localized in the nucleus and can be redistributed
by coexpression of p38 or p38 to the locations of p38 and p38. Mutations in the docking
groove on p38/p38, or the p38-docking site in PRAK, disrupted the PRAK-p38 interaction and
impaired the ability of p38 and p38 to redistribute ectopically expressed PRAK, indicating that
the location of PRAK could be controlled by its docking interaction with p38 and p38. Although
the majority of PRAK molecules were detected in the cytoplasm, PRAK is consistently shuttling
between the cytoplasm and the nucleus. A sequence analysis of PRAK shows that PRAK contains
both a putative nuclear export sequence (NES) and a nuclear localization sequence (NLS). The
shuttling of PRAK requires NES and NLS motifs in PRAK and can be regulated through cellular
activation induced by stress stimuli. The nuclear content of PRAK was reduced after stimulation,
which resulted from a decrease in the nuclear import of PRAK and an increase in the nuclear
export of PRAK. The nuclear import of PRAK is independent from p38 activation, but the nuclear
export requires p38-mediated phosphorylation of PRAK. Thus, the subcellular distribution of
PRAK is determined by multiple factors including its own NES and NLS, docking interactions
between PRAK and docking proteins, phosphorylation of PRAK, and cellular activation status.
The p38 MAPKs not only regulate PRAK activity and PRAK activation-related translocation, but
also dock PRAK to selected subcellular locations in resting cells.
INTRODUCTION
Mitogen-activated protein kinases (MAPKs) are activated in
response to a variety of extracellular stimuli (Nishida and
Gotoh, 1993; Davis, 1994; Waskiewicz and Cooper, 1995;
Cohen, 1996; Kyriakis and Avruch, 1996; Su and Karin, 1996;
Brunet and Pouyssegur, 1997; Robinson and Cobb, 1997;
Nebreda and Porras, 2000). The p38 group of kinases be-
longs to the MAPK family and plays an important role in cell
proliferation, cell differentiation, cell death, development,
and immune responses (Ono and Han, 2000). p38 MAPKs
exert their function partially through their downstream ki-
nases (Ono and Han, 2000). There are at least six protein
kinases that can be regulated by p38 and/or p38. These
downstream kinases of p38s include MAPK-activated pro-
tein kinase 2 (MAPKAPK2 or MK2; Stokoe et al., 1992),
MAPKAPK3 (Ludwig et al., 1996), MAPK-interacting kinase
1 (MNK1; Fukunaga and Hunter, 1997), MNK2 (Waskiewicz
et al., 1997), p38-activated/regulated protein kinase (PRAK
or MAPKAPK5; New et al., 1998; Ni et al., 1998), and mito-
gen- and stress-activated protein kinase (MSK; Deak et al.,
1998; New et al., 1999). Several downstream targets of this
family of kinases have been discovered, which include small
heat shock protein, cAMP response element binding protein
(CREB; Iordanov et al., 1997), serum response factor (SRF;
Heidenreich et al., 1999), and the basic helix-loop-helix
(HLH) protein E47 (Neufeld et al., 2000). Knockout mice of
MAPKAPK2 have been generated and the mice have shown
an ability to survive endotoxin shock (Kotlyarov et al., 1999).
The lack of MAPKAPK2 results in changes in translation
efficiency and the mRNA stability of different cytokines
(Winzen et al., 1999).
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To precisely transduce signaling, the proteins in the sig-
naling pathway need to recognize and interact with specific
upstream and downstream partners. A number of scaffold
or anchor proteins were found to facilitate the efficiency and
secure the fidelity of signaling transductions (Le Cabec et al.,
1997; Schaeffer et al., 1998; Whitmarsh and Davis, 1998;
McDonald et al., 2000). At the submolecular level, great
advances have been made in recent years enabling the iden-
tification of domain structures for protein-protein interac-
tions (Hunter, 2000). The structure of a given domain deter-
mines what the other domain(s) can interact with. A
common docking (CD) domain required for the interaction
with upstream and downstream kinases has been identified
in MAP kinases including p38 (Tanoue et al., 2000). Mu-
tagenesis studies reveal that this domain does not determine
the specificity of the interaction, and a sequence further
upstream serves as a determinant of specificity (Hotchkiss et
al., 1999). Recently, crystal structures of p38 bound to dock-
ing sites on its substrate or activator have been determined.
Structural analysis reveals that the CD domain does not
directly interact with the substrate or the activator, and two
new residues on the docking groove have been identified to
be critical for binding (Chang et al., 2002). The domain
structures of MAPKAPK2 were recently studied. Both the
nucleus location sequence (NLS) and the nucleus export
sequence (NES) were identified in MAPKAPK2 (Engel et al.,
1998). MAPKAPK2 was primarily localized in the nucleus
and transported into the cytoplasm upon extracellular stim-
ulation with a number of different stress stimuli (Ben-Levy et
al., 1998b; Engel et al., 1998). Translocation of MAPKAPK2
into the cytoplasm may allow the kinase to reach its cytoso-
lic substrates. Interestingly, the nuclear export of MAP-
KAPK2 also serves as a mechanism to bring the p38 that
docked to MAPKAPK2 into cytoplasm (Ben-Levy et al.,
1998b). The export of MAPKAPK2 into the cytoplasm re-
quires the phosphorylation of T317 by p38, but not of T205
within the activation loop. The nuclear export of MAP-
KAPK2 is sensitive to leptomycin B, an inhibitor of nucleus
export that binds to chromosomal region maintenance 1
(CRM1) protein, a nuclear export receptor for proteins car-
rying the leucine-rich NES (Ossareh-Nazari et al., 1997; En-
gel et al., 1998; Kudo et al., 1998).
PRAK can be activated in response to cellular stress and
proinflammatory cytokines. PRAK activity was regulated by
p38 and p38 in vitro and in vivo through phosphoryla-
tion. T182 within the activation loop of PRAK has been
determined to be the regulatory phosphorylation site (New
et al., 1998). Small heat shock protein 27 (Hsp27) and the
regulatory light chain of myosin II have been shown to be
the potential substrates of PRAK (New et al., 1998). PRAK
may play a role in balancing other MAPK pathways because
overactivation of PRAK can inhibit Ras mediated cell pro-
liferation and gene activation (Tanoue et al., 2001). Current
available data of PRAK show almost no difference between
PRAK and MAPKAPK2 in their activation profile and sub-
strate specificity. However, PRAK should have different
functions in comparison with MAPAK2 because it cannot
compensate for MAPKAPK2 deficiency in cells.
Because of the importance of subcellular location in pro-
tein function, we studied the regulation of PRAK subcellular
localization. We found that PRAK is localized predomi-
nantly in the cytoplasm and is constantly shuttled between
the cytoplasm and the nucleus. We have mapped domain
sequences that are required for PRAK localization and trans-
location and have shown that the location of PRAK in rest-
ing and activated cells is determined by multiple factors.
MATERIALS AND METHODS
Reagents
SB203580 was purchased from Calbiochem (San Diego, CA). Ani-
somycin, sodium arsenate, M2 anti-Flag antibody and immunopre-
cipitation beads, myelin basic protein (MBP), antifade mounting
solution, and leptomycin B were purchased from Sigma-Aldrich (St.
Louis, MO). TNF- was purchased from R&D systems (Minneapo-
lis, MN). Polyclonal antibodies against green fluorescent protein
(GFP) were purchased from ClonTech (Palo Alto, CA). FITC-labeled
secondary antibodies were purchased from BD PharMingen (La-
Jolla, CA), and the polyclonal antibodies against p38, p38, PRAK,
and MAPKAPK-2 were generated from New Zealand white rabbits
by stepwise subcutaneous and muscle injections of each of the
affinity-purified recombinant proteins described previously (New et
al., 1998).
Construction of Protein Expression Vectors
All of the his-tagged recombinant proteins were cloned downstream
of a T7 RNA polymerase promoter in the pETm1vector through
direct insertion of PCR fragments containing full-length coding
regions of different genes as describe before (Malinin et al., 1997).
The GFP-C1 vector from ClonTech is used for all of the GFP-fusion
constructs, and the target genes are constructed downstream and
in-frame to the GFP. HA-tagged PRAK is in the pcDNA3 vector as
described elsewhere (New et al., 1998), and Flag-tagged p38 and
p38 are also cloned in the pcDNA3 vector, but with a Flag-tag
sequence 5 to the target genes (Ge et al., 2002). The cDNA of a p38
splicing variant (also called p382 or p38–2; Stein et al., 1997)
encoding 364 amino acids was used. Various mutations in PRAK
and p38 or p38 in different vectors are created by using the Quick
Change kit (Stratagene, La Jolla, CA) with designed corresponding
pairs of mutagenic oligonucleotides. Each mutation was confirmed
by DNA sequencing of the whole target gene.
Cell Culture and Transfection
Hela cells and HEK293 cells were maintained in high-glucose Dul-
becco’s modified Eagle’s medium plus 10% FBS at 37°C in a humid-
ified 5% CO2 atmosphere. In the case of timed microscopic photog-
raphy of living cells, room temperature and a normal laboratory
atmosphere was applied. The transfection of protein expression
vectors was done by using Lipofectamine 2000 (Invitrogen, San
Diego, CA) following the vender’s protocol. Briefly, Hela or HEK293
cells were freshly seeded to 70% confluence 1 d before transfection.
The total DNA, 1–2 g, was mixed with 3 l of Lipofectamine 2000
in 200 l of nonserum medium for 30 min before dripping onto the
cells. Analysis of transfected gene expression took place within 24 h.
Immunostaining and Fluorescent Microscopy
Antisera containing polyclonal IgG to p38, p38, PRAK, and MAP-
KAPK-2 were subjected to antigen-specific affinity purification as
follows: 0.45-m nitrocellulose membrane saturated with purified
recombinant protein (600 g protein in 0.8 ml) was air-dried com-
pletely. Then the membrane was incubated in 1 ml of buffer A (5%
BSA, 10 mM Tris, 0.15 M sodium chloride, and 0.2% NP-40, pH 7.4)
for 30 min, and placed in fresh buffer A for another 5 min. The
membrane was incubated with the corresponding antiserum (1 ml)
for 2 h with gentle agitation and then washed three times with 1
PBS. The membrane bound antibodies were eluted in 200 l of
elution buffer (100 mM glycine, pH 2.5, adjusted with hydrogen
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chloride) and immediately neutralized by adding 0.1 ml of 1 M Tris
(pH 8.0). The concentration of purified antibodies was 0.1 mg/ml.
For immunostaining, differently treated cells growing on glass
chamber slides were fixed with 4% of 1 PBS-buffered formalde-
hyde for 10 min, followed by incubation in methanol/acetone (1:l)
at 20°C for 5 min. After washing with PBS, the slides were incu-
bated in blocking buffer (10% goat serum, 0.1% Tween 20 in PBS) for
1 h followed by incubation with the corresponding purified first
antibody (1:200) in fresh blocking buffer for 1 h. The slides were
washed with wash buffer (1 PBS plus 0.1% Tween 20) twice and
one more wash in wash buffer containing 10% BSA. The slides were
incubated in blocking buffer containing the FITC-labeled secondary
antibody for 50 min followed by washing three times in wash buffer
and three times in water. Slides were then mounted with antifade
solution, and the cover slips were sealed with nail polish.
GFP-fusion fluorescent-emitting cells or FITC-labeled cells were
viewed on an inverted Axiovet 200M microscope, and images were
captured through a 100 objective lens by a Carl Zeiss Vision digital
camera (Carl Zeiss, Oberkochen, Germany).
For quantitative fluorescence analysis, photos were captured in
the z-Plane at a 0.3-m intervals and then the volume was decon-
voluted by using a regulated-inversion filter program. A quantita-
tive program measuring intensities of fluorescent particles was
used. Individual cells were selected, and the cytoplasmic and nu-
clear fluorescent intensities were measured separately. After nor-
malizing the background in the same field, the value of nuclear
intensity of one cell is then divided by the cytoplasmic intensity of
the same cell to obtain LI (localization index; Chan and Chan, 1999).
Forty individual cells from four different views of microphoto-
graphs were subjected to this measurement. The mean of LI and the
SD of LI from two differently treated groups of cells were calculated
and compared.
Coimmunoprecipitation and Western Analysis
Mixture of two different plasmid DNAs (1:1) totaling 3 g was
cotransfected in HEK293 cells with Lipofectamine 2000. Twenty-
four hours after transfection, the cells were lysed by chilled 1 lysis
buffer (New England Bio-Labs, Beverly, MA) and then collected in
a microfuge tube. Cell lysate was incubated with 20 l of M2 beads
(anti-Flag) for 4 h at 4°C followed by stringent washing several
times. Samples were boiled to fully denature the proteins for 5 min
followed by SDS-PAGE gel analysis. To detect coimmunoprecipi-
tated proteins, Western blots were performed as described (New et
al., 1998). Anti-GFP antibodies were used to probe the coimmuno-
precipitated proteins, and the antiflag antibodies were then used to
probe the Flag-tagged proteins.
Immune Complex Kinase Assay
Cells, after 24 h of transfection or cotransfection of the kinase
expression vectors, were treated with or without TNF- for a period
of time as indicated and then washed in cold PBS buffer and lysed
in 0.8 ml of chilled 1 lysis buffer. Cell lysates were collected in
microfuge tubes and centrifuged for 15 min at 4°C. The superna-
tants were transferred to new tubes and incubated with 20 l of
anti-GFP beads (Santa Cruz) or anti-Flag M2 beads at 4°C for 4 h.
The beads bound with kinase samples were centrifuged and washed
in 1 PBS buffer twice and in 1  kinase buffer (New England
Bio-Labs) once. At this point, total amount of immune complex of
anti-GFP or M2 beads, from each sample, was split into two equal
volume parts. One part was used for kinase assay and the other part
saved for Western analysis to justify the amount of each immune
complex obtained through the process. The kinase reaction for
PRAK were carried out in a total volume of 60 l in 1 kinase buffer
containing the immune complex, 10 Ci of [-32P]ATP, and 10 g of
Hsp 27 prepared as before (New et al., 1998) at 37°C for 40 min with
shacking. The reaction was terminated by adding 30 l of SDS
loading buffer. The activities of immunoprecipitated p38 and p38
with their corresponding mutants were assayed as that of PRAK
described above except that 10 g of MBP was used as kinase
substrate. The kinase reaction samples were boiled for 5 min before
SDS-PAGE, and the extent of protein phosphorylation was analyzed
by phosphoimaging. The control Western analysis with anti-GFP
antibody or with anti-Flag antibody was performed as described
above.
RESULTS
Subcellular Location of PRAK
To better understand the regulation and function of PRAK,
we used immunostaining to determine the subcellular loca-
tion of PRAK. Anti-PRAK polyclonal antibodies, raised with
recombinant PRAK, were affinity-purified with immobi-
lized-PRAK protein and used in the immunostaining. As
shown in Figure 1A, a predominantly cytoplasmic stain of
PRAK was exhibited in HEK293 (293) and Hela cells, with
the brightest staining shown peripherally around the nu-
cleus and extending to the distal cytoplasm.
PRAK Is Constantly Shuttling between Nucleus and
Cytoplasm
To determine if PRAK traffics between the cytoplasm and
the nucleus, we treated 293 (Figure 1B) and Hela (our un-
published results) cells with leptomycin B (LMB), a specific
inhibitor of nuclear export that interferes with the binding of
the leucine-rich NES to the export receptor exportin 1 (Os-
sareh-Nazari et al., 1997). PRAK was found to rapidly accu-
mulate in the nucleus of the LMB-treated cells (Figure 1B,
middle panel), implying constant trafficking of PRAK be-
tween the cytoplasm and the nucleus under normal condi-
tions. However, when the cells were stimulated with tumor
necrosis factor- (TNF) for 2 h, the nuclear stain of PRAK
appeared to be reduced (Figure 1B). To statistically assess
the effect of TNF on translocation of PRAK, we measured the
intensity of FITC stain in the nucleus and cytoplasm of each
individual cell from a total of 40 cells treated with or without
TNF-, respectively, using an interactive particle-volume
measuring software program (Carl Zeiss). The ratio of nu-
clear over cytoplasmic florescence intensity was operation-
ally defined as the LI (Chan et al., 1996; Chan and Chan,
1999) and calculated for each cell measured. The LI mean LI
SD for TNF-treated cells is 0.15 0.03, whereas for non–TNF-
treated cells is 0.31  0.04. The value of LI SD from the two
groups is close, but the value of LI mean from TNF-treated
cells is substantially smaller than that of nontreated cells.
TNF stimulation increases PRAK nucleus export and/or
decreases PRAK transport into the nucleus.
Docking of PRAK to Proteins such as p38 and
p38 Plays a Key Role in the Subcellular
Localization of PRAK
Fusion of GFP with a protein of interest has proven to be
very useful in studying the subcellular location of the pro-
tein. To investigate PRAK translocation, we made use of the
GFP-PRAK fusion system. As shown in Figure 1C, in con-
trast to endogenous PRAK, GFP-PARK is mainly located in
the nucleus of 293 cells. The same result was obtained when
using Hela cells (our unpublished results). To exclude the
possibility that the nuclear localization of GFP-PRAK is
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caused by GFP, we transfected GFP expression vectors into
the cells and observed the diffused distribution of GFP in
both the nucleus and the cytoplasm (our unpublished re-
sults). We also expressed HA-tagged PRAK in 293 (Figure
1D) and Hela (our unpublished results) cells and stained
these cells with the anti-PRAK antibody. The HA-tagged
PRAK in the transfected cells was detected in the nucleus,
which is consistent with the GFP-PRAK subcellular localiza-
tion and suggests that ectopically expressed PRAK is in
different subcellular locations than the endogenous protein.
It is well accepted that cellular transport systems play a
key role in sorting the different proteins into their distinct
subcellular compartments. However, the subcellular loca-
tion of a given protein may also be influenced by its inter-
acting proteins. The nuclear location of ectopically overex-
pressed PRAK may be caused by the fact that there is
insufficient amount of corresponding PRAK-interacting pro-
teins to dock PRAK, thus causing PRAK molecules to be
sorted into the nucleus. To test this hypothesis, we examined
whether the upstream kinases of PRAK, p38, and p38 that
interact with PRAK have any effect on the location of GFP-
PRAK. This was done by coexpressing GFP-PRAK with
p38 or p38 in 293 (Figure 1E) and Hela cells (our unpub-
lished results). Coexpression of p38 with GFP-PRAK
caused GFP-PRAK to redistribute to both the nuclear and
cytoplasmic locations (Figure 1E, left panel), whereas coex-
pression of p38 with GFP-PRAK resulted in GFP-PRAK to
predominate in the cytoplasm(Figure 1E, right panel).
Therefore, the location of GFP-PRAK appears to be con-
trolled by coexpression of both p38 and p38, because
p38 is located in the nucleus and the cytoplasm (Figure 1F,
left panel), and p38 is located predominantly in the cyto-
plasm (Figure 1E, right panel). Collectively, the results
shown in Figure 1, C–F, demonstrate that the docking of
PRAK to other proteins could significantly affect the location
of PRAK and that p38 and p38 are among the molecules
that can dock to PRAK.
Shuttling of Endogenous PRAK Can Be Mimicked by
GFP-PRAK
Because docking of GFP-PRAK to p38 closely mimics en-
dogenous PRAK in subcellular locations, we examined
whether the trafficking of GFP-PRAK in this system is sim-
ilar to that of endogenous PRAK. We coexpressed GFP-
PRAK and p38 in 293 cells (Figure 2A) and treated these
cells with LMB (Figure 2A, middle panel) or TNF (Figure
2A, right panel). Similar to what we observed in Figure 1B
with endogenous PRAK, an increase in the nuclear GFP-
PRAK concentration became apparent when nuclear export
was inhibited, though some of the GFP-PRAK still remained
in the cytoplasm (Figure 2A, middle panel). As in the case of
the endogenous PRAK (Figure 1B, right panel), TNF treat-
ment reduced the nuclear GFP-PRAK concentration even
when p38 was coexpressed (Figure 2A, right panel). These
results indicate that GFP-PRAK, coexpressed with p38,
behaves similarly to endogenous PRAK in terms of constant
shuttling within resting cells and enhanced exporting of
GFP-PRAK from the nucleus to the cytoplasm in TNF-
treated cells. Taking advantage of the nuclear location of
GFP-PRAK (Figure 1C), we compared the effects of other
stimuli that are known to cause cellular stress similar to that
Figure 1. The subcellular loca-
tions and cytoplasm-nucleus
shuttling of endogenous PRAK.
(A) HEK293 and Hela cells were
fixed and immunostained with
anti-PRAK primary antibodies
and FITC-labeled secondary anti-
body. A representative microim-
age for each stain was shown.
PRAK is predominantly located
in cytoplasm of resting cells. (B)
HEK293 cells were treated with
nothing (), LMB (3 ng/ml) for
1 h, or TNF- (100 nM) for 2 h
and then fixed and stained with
anti-PRAK antibody. An appar-
ent accumulation of PRAK in the
nucleus was observed when nu-
clear export was blocked by LMB
(middle panel). TNF stimulation
reduced nuclear PRAK (right
panel, see text for the statistic
analysis). (C) HEK293 cells were
transfected with expression vec-
tor of GFP-PRAK. GFP-PRAK
was visualized under a fluores-
cent microscope 24 h after trans-
fection. Ectopically expressed
GFP-PRAK was localized in nucleus. (D) HEK293 cells were transfected with expression vector of HA-PRAK. The cells were fixed 24 h after
transfection and immunostained with anti-PRAK primary antibodies and FITC-labeled secondary antibody. Ectopically expressed HA-PRAK
was localized in nucleus. (E) HEK293 cells were transfected with expression vector of GFP-PRAK together with flag-p38 or flag-p38.
GFP-PRAK was visualized under a fluorescent microscope 24 h after transfection. Coexpression of p38 and p38 relocalized GFP-PRAK.
(F) HEK293 cells were fixed and immunostained with anti-p38 or anti-p38 antibodies and FITC-labeled secondary antibody.
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of TNF on the nuclear exportation of PRAK. As shown in
Figure 2B, TNF, anisomycin, and arsenite all induced export
of GFP-PRAK from the nucleus to the cytoplasm. These data
are consistent with the results obtained when using endog-
enous PRAK (Figure 1B, right panel and our unpublished
results).
PRAK Contains a Typical Leucine-rich NES and a
Bipartite NLS
Aligning the primary protein sequences of PRAK, MAP-
KAPK2, and MAPKAPK3 reveals that PRAK contains sim-
ilar NES and NLS (Figure 3A). The major difference between
PRAK and MAPKAPKs in these sequences is that one part of
NLS in PRAK is located inside the NES part. The putative
NES in PRAK is highly conserved to the prototypic NES
sequence from the inhibitor of protein kinase A, PKI (Wen et
al., 1995; Figure 3A). To determine whether the sequences
found in PRAK truly function as signals for nuclear export
and import, we assessed the requirement of the NES and
NLS in nuclear import and export of PRAK by the creation
of site-specific mutations in the two motifs (Figure 3A). The
NES mutant was made by changing the three leucines (L) in
the putative NES of PRAK to serines (S) and termed
PRAK(sss) (Figure 3A). The NLS mutant was made by con-
verting the stretch of four basic amino acids arginine-lysine-
arginine-lysine (RKRK) to glutamine-threonine-threonine-
glycine (QTTG; Figure 3A) and named PRAK(qttg). When
GFP-PRAK(sss) was expressed in 293 cells, it located in the
nucleus. TNF treatment could not drive this protein out of
the nucleus (Figure 3B, right panel), indicating that the
Figure 2. Translocation of GFP-
PRAK. (A) Expression vectors of
GFP-PRAK and flag-p38were co-
transfected into HEK293 cells.
Twenty-four hours after the trans-
fection, the cells were treated with
or without LMB or TNF- for var-
ious times as indicated. GFP-
PRAK in the same individual cells
was monitored by fluorescent mi-
croscopy. (B) HEK293 cells trans-
fected with GFP-PRAK expression
vector were subjected to a treat-
ments of TNF- (top panel), ainso-
mycin (15 g/ml; middle panel),
and arsenite (250 ; bottom pan-
el). The redistribution of GFP-
PRAK in the same individual cells
was monitored by fluorescent mi-
croscopy.
Translocation of PRAK
Vol. 14, June 2003 2607
putative NES was indeed required for PRAK export from
the nucleus. However, GFP-PRAK(qttg) was found to be
exclusively localized in the cytoplasm, and LMB failed to
accumulate GFP-PRAK(qttg) in the nucleus (Figure 3B, right
panel), confirming that the predicted nuclear location se-
quence is functional in PRAK.
We next determined kinase activities of GFP-PRAK(sss)
and GFP-PRAK(qttg) in comparison with that of GFP-PRAK
and GFP-PRAK(KM), a kinase dead mutant, by using im-
mune complex kinase assay. Small heat shock protein
(Hsp27) was used as substrate in the kinase assays. The
kinase activity of GFP-PRAK was enhanced 8–10-fold in
response to TNF stimulation, lasting for at least 2.5 h (Figure
3C, right panel). Wild-type GFP-PRAK had some basal ki-
nase activity, whereas a mutation in its ATP pocket [K51 to
M mutant, GFP-PRAK(KM)] eliminated kinase activity in
both resting and stimulation conditions (Figure 3C, right
panel). The NES mutant [GFP-PRAK(sss)] had similar basal
activity as GFP-PRAK and can be activated by TNF stimu-
lation (Figure 3C, right panel). The NLS mutant [GFP-
PRAK(qttg)] retained basal activity but cannot be regulated
by TNF stimulation. Because NLS in PRAK overlaps with
the p38 docking site (Engel et al., 1998; Tanoue et al., 2001)
and see Figure 6A), the unresponsiveness of NLS mutant to
TNF stimulation could be caused by a defect in translocation
to the nucleus or a defect in interacting with p38.
The Relation among T182 Phosphorylation, Kinase
Activity, and Location of PRAK
It has been demonstrated that the nuclear export of MAP-
KAPK2 is regulated by the phosphorylation on T317 located
in the C-terminal of the kinase domain. Sequence alignment
of PRAK and MAPKAPK2 (Engel et al., 1998; New et al.,
1998) revealed that PRAK does not have that corresponding
phosphorylation site. This indicates that a different regula-
tion mechanism may govern the nuclear exports of PRAK
and MAPKAPK2. It is known that T182 and S212 of PRAK
can be phosphorylated by p38, and the phosphorylation of
T182 upregulated PRAK kinase activity (New et al., 1998). To
address whether the phosphorylation and kinase activity of
PRAK affect the location and translocation of PRAK, we
used a series of PRAK mutants. The mutants are illustrated
in Figure 4A. The kinase activities of PRAK(182D),
PRAK(182, 212D), and PRAK(182A) were studied previ-
ously (New et al., 1998). Here we measured activities of GFP
fusion proteins of these PRAK mutants. T182 mutations
(either D or A mutant) abolished the responsiveness of
Figure 3. Requirement of NES
and NLS for nuclear export and
import of PRAK. (A) Sequence
alignment NES and NLS found in
PRAK, MAPKAPK2, and MAP-
KAPK3. The nuclear export se-
quence (NES) is shown shaded
and the nuclear localization se-
quence (NLS) is both boxed and
shaded. A prototypic NES se-
quence from PKI is shown on the
top of the sequence alignment. The
mutation sites of GFP-PRAK(sss)
and GFP-PRAK(qttg) are indicated.
(B) HEK293 cells were transfected
with expression vector of GFP-
PRAK(sss) or GFP-PRAK(qttg).
Twenty-four hours after transfec-
tion, the cells were treated with or
without TNF or LMB for time pe-
riods as indicated. The distribu-
tions of GFP were analyzed by flu-
orescent microscopy. (C) HEK293
cells were transfected with expres-
sion vector of GFP-PRAK, GFP-
PRAK(KM), GFP-PRAK(qttg), or
GFP-PRAK(sss). Twenty-four hours
after transfection, the cells were
treated with or without TNF for dif-
ferent time periods (left panel) or 2 h.
GFP-PRAK and its mutants were
immunoprecipitated with anti-GFP
antibodies. The kinase activity in
the immunoprecipitates was deter-
mined by in vitro kinase assay us-
ing Hsp27 as substrate. Equal
amounts of GFP-PRAK in the im-
munoprecipitates were deter-
mined by Western blotting with
anti-GFP antibodies.
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PRAK to TNF stimulation (Figure 4B), because these mu-
tants can no longer be phosphorylated by p38 at T182 (New
et al., 1998). GFP-PRAK(182D) and GFP-PRAK(182, 212D)
had a slightly higher basal activity than GFP-PRAK and
GFP-PRAK(182A), suggesting that the D replacement some-
what mimic the negative charge of phosphorylation (New et
al., 1998). GFP-PRAK(KM) is kinase-dead but it still can be
phosphorylated by p38 (Figure 3C and our unpublished
results). All of these mutants were localized in the nucleus
when expressed in 293 cells (Figure 4C, top panels), indicat-
ing that in resting cells these mutations do not influence the
transport of ectopically expressed PRAK into nucleus. How-
ever, TNF stimulation cannot lead to nucleus export of the
T182 mutants (Figure 4C, bottom panel), indicating a re-
quirement of T on the 182 site in the stimulation-mediated
nuclear export of PRAK. Because T182 was phosphorylated
after stimulation with TNF (New et al., 1998), it is most likely
that phosphorylation on T182 is required for the nuclear
export of PRAK. Being retained in the nucleus of the 182D
mutant after stimulation, suggests that the D mutant cannot
fully mimic the function of the phosphorylation on T182. In
contrast to the T182 mutants, GFP-PRAK(KM) is capable of
translocation into the cytoplasm after TNF treatment (Figure
4C, bottom panels), suggesting that PRAK kinase activity is
not required for nuclear export of PRAK.
The Docking of PRAK to p38 or p38 Requires
Docking Motifs on Both Proteins, But Not Kinase
Activities, or Functional Phosphorylations of Either
Proteins
A substrate-docking motif in p38 has been shown to be
required for interaction with PRAK (Tanoue et al., 2000,
2001). Because the coexpression of p38 or p38 causes
redistribution of GFP-PRAK and this redistribution is most
likely accomplished through an interaction with PRAK, we
examined whether the docking motifs in p38 or p38 and
in PRAK are required for their docking interaction and the
redistribution of GFP-PRAK to the cytoplasm. Mutations of
the docking motif in p38 and p38 were made as shown in
Figure 5A. Flag-tagged p38(nqn), p38(nqn), p38(AF), or
p38(AF) were coexpressed with GFP-PRAK in 293 cells.
The interaction of PRAK with the mutants of p38 or p38
was determined by coimmunoprecipitation. Apparently,
mutations of the substrate docking site in p38 and p38
abolished their interaction with PRAK, respectively (Figure
5B). In contrast to the mutations in the substrate docking
site, mutations on the phosphorylation sites in p38 and
p38 did not affect their interaction with PRAK (Figure 5B),
indicating that p38 phosphorylation and activity are not
required for docking PRAK. Consistent with the interaction
detected by coimmunoprecipitation, we found that
p38(nqn) and p38(nqn) can no longer redistribute GFP-
PRAK inside the cells, whereas p38(AF) and p38(AF)
behaved similarly to wild-type proteins by docking PRAK to
different subcellular locations (Figure 5C).
Immune complex kinase assays were performed to mea-
sure the kinase activities of p38, p38, and their mutants.
As expected, mutations on the phosphorylation sites or the
substrate docking motif abolished kinase activities of p38
and p38 (Figure 5D). Coexpression of p38(AF) or
p38(AF) mutant with GFP-PRAK inhibited TNF-stimulated
activation of GFP-PRAK (Figure 5E), which is consistent
with the dominant negative effect of these mutants (Huang
et al., 1997; Wang et al., 2000; Ge et al., 2002). In contrast, the
overexpression of docking motif mutants had no effect on
TNF-induced PRAK activation (Figure 5E). This can be in-
Figure 4. Nuclear export of
PRAK requires the regulatory
phosphorylation site T182 but not
kinase activity of PRAK. (A) A
schematic primary structure of
PRAK indicates the position of
the catalytic domain and the mo-
tifs of NES and NLS. Mutations
that altered the phosphorylation
sites (T182, S212) or ATP pocket
(K51) were shown under the
structure. (B) HEK293 cells were
transfected with the expression
vector of different GFP-PRAK
mutants as indicated. Twenty-
four hours after transfection, the
cells were treated with or without
TNF for 2 h. The kinase activity of
GFP-PRAK mutants was ana-
lyzed by immunokinase assay as
in Figure 3C. (C) HEK293 cells
were transfected with the expres-
sion vector of different GFP-
PRAK mutants as indicated.
Twenty-four hours after transfec-
tion, the cells were treated with
or without TNF for 2 h. The loca-
tions of GFP-PRAK were analyzed by fluorescent microscopy. TNF-induced nuclear export of GFP-PRAK was impaired by mutations on
T182 site but not by a mutation in ATP pocket.
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terpreted by the fact that overexpression of flag-p38(nqn)
or flag-p38(nqn) cannot compete with endogenous p38 for
substrates and upstream activators because nqn mutants of
p38 and p38 cannot bind with downstream substrates
(Tanoue et al., 2001 and Figure 5B) or upstream MKKs
(Tanoue et al., 2000).
The docking sites in MAPKAPK2 have been mapped to
the C termini of the protein and overlapped with NLS. The
NLS in PRAK (Figure 6A) has also proved to be a motif
essential for p38 docking in a coimmunoprecipitation exper-
iment (Engel et al., 1998; Tanoue et al. 2001). To ascertain the
function of this motif in docking, we coexpressed GFP-
PRAK(qttg) with flag-p38 or flag-p38. Coimmunoprecipita-
tion assays show that PRAK(qttg) fails to interact with p38 or
p38 (Figure 6B). In contrast, mutations of the phosphorylation
sites or ATP pocket of PRAK can still be coimmunoprecipitated
with p38 (our unpublished results) or p38 (Figure 6B). Mu-
tations of NES in PRAK impaired stimulus-mediated nuclear
exports of PRAK (Figure 3) but had no effect on the interaction
with p38 (our unpublished results) and p38 (Figure 6B). In
support of the notion that the docking interaction controls the
subcellular location of PRAK, the subcellular location of GFP-
PRAK(qttg) cannot be influenced by coexpressed p38 or p38
(Figure 6C). In contrast, the mutations on the phosphorylation
sites or ATP pocket of PRAK did not have any effect on the
relocation of PRAK by p38 (Figure 6C). Thus, the phosphor-
ylation and activity of p38 and PRAK appear not to affect the
docking interactions between the two proteins. It was observed
that the cells coexpressing flag-p38 and GFP-PRAK(sss) have
certain levels of GFP-PRAK(sss) in the cytoplasm (Figure 6C,
bottom-right panel). This cytoplasm-retained GFP-PRAK(sss)
is most likely caused by the p38 docking of this protein after
its synthesis in the cytoplasm, but before its nuclear import,
because nuclear GFP-PRAK(sss) cannot be exported out of the
nucleus.
The results of transfection and cotransfection experiments
with wild-type or mutants of PRAK and p38 are summa-
rized in the Table 1.
TNF Stimulation Affects Both Nuclear Export and
Import of PRAK
We showed earlier in Figures 1B and 2 that TNF stimulation
led to the nuclear export of PRAK or GFP-PRAK and that the
export requires T182 in PRAK (Figure 4). To determine
whether p38 activity is required for the nuclear export of
PRAK, we expressed GFP-PRAK in 293 cells and treated
these cells with TNF in the presence or absence of SB203580.
As shown in Figure 7A, SB203580 prevented the TNF-in-
duced nuclear export of PRAK. Thus, TNF-induced nuclear
export of PRAK is p38 dependent.
The reduction of nuclear PRAK by extracellular stimula-
tion can be achieved by either a decrease of nuclear import
or an increase of nuclear export of PRAK. To determine
whether the nuclear import of PRAK was altered when the
cells were stimulated with TNF, we treated 293 cells with
LMB together with or without TNF. The cells were fixed at
different times after treatment and stained with the anti-
PRAK antibody. The same result was obtained as was
shown earlier in Figure 1. LMB treatment led to a rapid
accumulation of PRAK in the nucleus (Figure 7B, top panel).
TNF treatment dramatically reduced LMB-mediated nuclear
Figure 5. A substrate docking
motif on p38 but not the regula-
tory phosphorylation or activity
of p38 controls the docking inter-
action with PRAK. (A) A sche-
matic structure of p38 and p38
shows the positions of the cata-
lytic domain and a substrate
docking motif on p38. The key
amino acid residues in these mo-
tifs were presented as bold let-
ters. The mutation sites of
p38(AF) and p38(nqn) are indi-
cated. (B) HEK293 cells were co-
transfected with various combi-
nations of p38 and GFP-PRAK
expression vectors as indicated.
The cell lysates were collected
24 h after transfection and immu-
noprecipitated with the antiflag
antibody M2. The presence of
GFP-PRAK or flag-p38 in the im-
munoprecipitates was deter-
mined by Western blotting using
antiGFP or antiflag antibodies, re-
spectively. (C) HEK293 cells were
transfected as in B and the subcellular locations of GFP-PRAK were analyzed by fluorescent microscopy. (D) The mutants of p38 or p38
were expressed in HEK293 cells as indicated. Twenty-four hours after transfection, the cells were treated with or without TNF for 2 h. The
cell lysates were then collected and immunoprecipitated with the antiflag antibody M2. The kinase activity of p38 mutants was measured by
immunokinase assay using MBP as substrate. The equal amount of p38 or p38 in the immunoprecipitates was determined by Western
blotting. (E) HEK293 cells were cotransfected with various combinations of p38 mutants and GFP-PRAK expression vectors as indicated.
Twenty-four hours after transfection, the cells were treated with or without TNF for 2 h. The cell lysates were collected and immunopre-
cipitated with the anti-GFP antibodies. The kinase activity of GFP-PRAK was determined by immunokinase assay as in Figure 3C.
L. New et al.
Molecular Biology of the Cell2610
localization of PRAK (Figure 7B, middle panel). We used
LI  1.0, e.g., the level of nuclear PRAK was equal to or
greater than the amount of cytoplasmic PRAK, as a standard
for nuclear accumulation of PRAK to compare the difference
in nuclear import between the cells treated with or without
TNF. As shown in Figure 7C, almost all cells showed nuclear
accumulation of PRAK within 1 h of LMB treatment,
whereas TNF treatment reduced the cell number to10% of
the population. Longer time treatment of LMB did not ap-
pear to overcome TNF’s effect because there was only 30% of
the cells showing nuclear accumulation of PRAK 3 h after
treatment.
To test whether TNF-induced activation of p38 and/or
p38 has any role in TNF’s effect on PRAK nuclear import,
Figure 6. The basic cluster of
amino acids in the docking site
on PRAK but not the regulatory
phosphorylation site on PRAK or
activity of PRAK, determines the
docking interaction with p38. (A)
A schematic representation of
PRAK shows the relative position
of the catalytic domain, NES,
NLS, and the docking site. The
docking site overlaps with NLS.
(B) Coimmunoprecipitation as-
says of various GFP-PRAK mu-
tants with flag-p38 or flag-p38
were performed as described in
Figure 5B. (C) The effects of dif-
ferent mutations in PRAK on the
redistribution of GFP-PRAK by
the coexpression of flag-p38 or
flag-p38 was evaluated using
the same method as in Figure 5C.
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we treated the cells with TNF in the presence of SB203580.
As shown in Figure 7B, the inhibition of p38 and p38 did
not interfere with TNF-reduced nuclear import of PRAK.
Thus, TNF-mediated reduction of the nuclear import of
PRAK is independent of p38 activation.
DISCUSSION
We studied subcellular localization and shuttling of PRAK
and concluded that 1) PRAK is predominantly localized in
cytoplasm. 2) PRAK is constantly shuttled between the cy-
toplasm and the nucleus. The NLS and NES identified in
PRAK are required for the shuttling. Because almost all
PRAK proteins were accumulated in nucleus when nuclear
export was inhibited, we conclude that all of the PRAK
molecules are involved in the circulation between the cyto-
plasm and the nucleus. 3) The cytoplasmic location of en-
dogenous PRAK is most likely caused by a docking interac-
tion with p38 because overexpressed “free” PRAK
localized in nucleus and the coexpression of p38, a cyto-
plasmic PRAK interaction protein that relocalized PRAK
into the cytoplasm. The docking interaction requires dock-
ing motifs identified in PRAK and p38 or p38 and is not
influenced by the phosphorylation status and activity of
these kinases. 4) Phosphorylation of PRAK on T182 is an
event required for the nuclear export of PRAK or an event
that facilitates the nuclear export of PRAK. 5) Cell activation
by extracellular stimuli can alter the nuclear import and
export of PRAK. Stimulation of cells with TNF reduced the
nuclear import of PRAK in a p38-independent manner and
increased the nuclear export of PRAK by a p38-dependent
mechanism.
On the basis of our data, we propose a model for the
regulation of PRAK localization and shuttling by p38
MAPKs (Figure 8). The majority of PRAK localized in the
cytoplasm, docking by cytoplasmic p38. The p38 docking
site in PRAK overlaps with the NLS region; therefore, the
interaction of PRAK with p38 likely masks this site, which
may account for a mechanism in preventing the nuclear
import of PRAK. It is clear that the balance is in favor of
PRAK and p38 binding in the cytosol. However, there
should be some remaining free PRAK. The free PRAK can be
imported into the nucleus, which may account for the low
level of nuclear PRAK in resting cells. Overexpressed PRAK
located primarily in nucleus, suggesting that either the nu-
clear export signal of PRAK is not as predominant as the
nuclear import signal or the NES of PRAK was masked
intramolecularly or intermolecularly by other protein(s),
thus preventing or reducing the speed of the nuclear expor-
tation of PRAK. The docking interaction between PRAK and
p38 should occur in the nucleus. The basal and stimulated
activity of p38 should be responsible for the phosphoryla-
tion of nuclear PRAK in resting and activated cells, respec-
tively. Nuclear exportation of PRAK may require the phos-
phorylation of PRAK or at least enhanced by this
phosphorylation. We proposed that the phosphorylation of
PRAK by p38 unmasks MES in PRAK and results in the
subsequent nuclear export of PRAK. TNF stimulation re-
duces the nuclear import of PRAK, using an unknown
mechanism, and increases the nuclear export of PRAK in a
p38-dependent manner. Because most of the experiments
described in this report have to use overexpression systems,
the model shown in Figure 8 could be oversimplified, in-
complete, and imbalanced. The docking effect of p38 and
p38 on PRAK subcellular localization needs to be con-
firmed when p38 and p38 knockout cells are available.
While this manuscript was in revision, Seternes et al.
(2002) reported a study on PRAK (MAPKAPK5) subcellular
localization. They also mapped NLS and NES motifs on
PRAK and concluded that PRAK can shuttle between nu-
cleus and cytoplasm. But different from us, they concluded
that PRAK is a nuclear protein. Because the same type of
cells was used by Seternes and us, the controversial results
cannot be caused by cell type differences. To address this
conflicting result, we have repeated our experiments with
anti-PRAK antibodies from different rabbits. We have anti-
bodies from four different rabbits that can selectively detect
PRAK but not MAPKAPK2 in Western blotting analysis. We
immuno-purified the different anti-PRAK antibodies and
used them in immunostaining experiments. Just as in the
result we obtained earlier (Figure 1A), PRAK was detected
predominantly in cytoplasm by the antibodies from different
rabbits (our unpublished results). The specificity of these
antibodies in staining PRAK was further confirmed by their
staining of ectopically expressed PRAK in nucleus (Figure
1D and our unpublished results). Thus, we have no doubt
that the majority of PRAK molecules are localized in cytosol.
Table 1. Subcellular location of GFP-PRAKs
GFP-PRAK
Cotransfected
with
GFP-PRAK
localization
GFP-PRAK — Nucleus
GFP-PRAK Flag-p38 Nucleus and
cytoplasm
GFP-PRAK Flag-p38 Cytoplasm
GFP-PRAK Flag-p38(AF) Nucleus and
cytoplasm
GFP-PRAK Flag-p38(AF) Cytoplasm
GFP-PRAK Flag-p38(nqn) Nucleus
GFP-PRAK Flag-p38(nqn) Nucleus
GFP-PRAK(182A) — Nucleus
GFP-PRAK(182A) Flag-p38 Nucleus and
cytoplasm
GFP-PRAK(182A) Flag-p38 Cytoplasm
GFP-PRAK(182D) — Nucleus
GFP-PRAK(182D) Flag-p38 Nucleus and
cytoplasm
GFP-PRAK(182D) Flag-p38 Cytoplasm
GFP-PRAK(182, 212D) — Nucleus
GFP-PRAK(182, 212D) Flag-p38 Nucleus and
cytoplasm
GFP-PRAK(182, 212D) Flag-p38 Cytoplasm
GFP-PRAK(KM) — Nucleus
GFP-PRAK(KM) Flag-p38 Nucleus and
cytoplasm
GFP-PRAK(KM) Flag-p38 Cytoplasm
GFP-PRAK(qttg) — Cytoplasm
GFP-PRAK(qttg) Flag-p38 Cytoplasm
GFP-PRAK(qttg) Flag-p38 Cytoplasm
GFP-PRAK(sss) — Nucleus
GFP-PRAK(sss) Flag-p38 Nucleus
GFP-PRAK(sss) Flag-p38 Nucleus and
cytoplasm
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Previous characterization of PRAK showed its similarity
to its homologue MAPKAPK2 in the activation profile and
substrate specificity (New et al., 1998). Here we show that
similar to MAPKAPK2, cellular stresses also stimulate nu-
cleus export of PRAK (Figures 1B and 2). The major differ-
ence between these two proteins found so far is subcellular
localization in resting cells (Figure 1A and our unpublished
results). The difference in the subcellular localization of
Figure 7. Regulation of PRAK
shuttling by TNF stimulation. (A)
HEK293 cells transfected with the
expression vector of GFP-PRAK
were treated with or without
TNF in the presence or absence of
SB203580 (20 M) for 2 h. The
subcellular location of GFP-
PRAK was examined by fluores-
cent microscopy. The p38 inhibi-
tor SB203580 inhibited TNF-
induced exportation of GFP-
PRAK. (B) HEK293 cells were
treated with LMB together with a
vehicle (0.1% methanol and 0.1%
DMSO)(Ctrl), TNF or TNF
SB203580 for the time periods as
indicated. The cells were fixed
and location of PRAK was ana-
lyzed by immunostaining as in
Figure 1A. (C) The relative speed
of PRAK translocation from the
cytoplasm into the nucleus was
estimated by counting cells,
whose nuclear PRAK staining
was equal to, or higher than, the
cytoplasmic staining (LI  1.0,
see text for detail) from a popu-
lation of 60 cells. The percentages
of these cells in TNF-treated and
untreated samples were calcu-
lated and shown.
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PRAK and MAPKAPK2 is probably caused by different
docking interactions. Docking interactions may play a role
in controlling the location or translocation of certain pro-
teins. For example, the docking interaction between
MEK1and ERK1 was reported to be important for the cyto-
plasmic location of ERK1 (Fukuda et al., 1997). The translo-
cation of p38 from the nucleus to the cytoplasm in stress-
activated cells was mediated by its binding partner,
MAPKAPK2 (Ben-Levy et al., 1998b). p38 can redistribute
GFP-MAPKAPK3 by interacting with it (Tanoue et al., 2001).
However, the effect of docking interactions on PRAK local-
ization shows some differences from the reported studies.
MAPKAPK2 directs translocation of p38, whereas subcel-
lular localization of PRAK is directed by p38 or p38
(Figure 1). Also, unlike the ERK1 that anchored in the cyto-
plasm and was translocated to nucleus after phosphoryla-
tion, the activation of PRAK by p38 did not lead to the
translocation of PRAK to the nucleus. Furthermore, the nu-
clear location of overexpressed ERK1 appeared to be inde-
pendent of NLS-mediated translocation (Fukuda et al., 1997),
whereas the accumulation of ectopically expressed PRAK is
dependent on the NLS of PRAK (Figure 3). Nevertheless,
our work and the works referenced above demonstrate that
the docking interactions can play a very important role in
determining the subcellular location of protein kinases in
resting as well as in activated cells. Because docking with
other proteins can play a key role in subcellular localization
of a given protein, caution needs to be given when overex-
pression is used to study subcellular localizations of a pro-
tein.
Some proteins, such as mitochondrial proteins, never
come back to the cytoplasm once their destination has been
reached (Gorlich, 1998), whereas other proteins are con-
stantly trafficking between two cellular compartments such
as the nucleus and the cytoplasm (Gorlich, 1998; Murata et
al., 2002). It was believed that small proteins have the po-
tential to freely diffuse through the nuclear pore, whereas
proteins 	60 kDa are subjected to active and carrier medi-
ated transport (Gorlich, 1998). PRAK is a 50-kDa protein but
seems unable to freely travel between the nucleus and the
cytoplasm. The nuclear import of PRAK is mediated by a
process of NLS-dependent protein import, and its nuclear
export requires CRM1.
PRAK functions downstream of p38 to mediated cellular
responses. However, the precise role of PRAK is not clear.
As with other shuttling proteins, the nucleus and cytoplasm
circulation of PRAK must have a role in normal cell physi-
ology. Alteration of shuttling in activated cells should be a
part of the cellular response to extracellular stimuli, and its
effects deserve further investigation. An increased export of
PRAK in TNF-treated cells may permit PRAK to be activated
in the nucleus, thereby phosphorylating cytoplasmic sub-
strates. Because p38 can be activated by a similar panel of
extracellular stimuli as p38 (Jiang et al., 1996; Kumar et al.,
1997; Nemoto et al., 1998), we reason that cytoplasmic PRAK
can be activated by cellular stress too. It is possible that the
nuclear export of activated PRAK in stress-activated cells is
a cellular response to compensate for a shortage of activated
PRAK in the cytoplasm. But given the fact that the majority
of PRAK was found in the cytoplasm, the nuclear export of
a small amount PRAK may not have a significant effect if the
exported PRAK executes the same function as the cytoplas-
mic PRAK. It is also possible that PRAK exported from the
nucleus has a different function than the PRAK activated in
the cytoplasm. The 182D mutant of PRAK gained certain
levels of kinase activity (New et al., 1998) but could not be
exported from the nucleus (Figure 4). Instead of acting as a
dominant active mutant, PRAK(182D) has been reported to
interfere with Ras-mediated cell proliferation (Chen et al.,
2000). So the dominant negative effect of PRAK(182D) may
not be caused by a defect in the kinase activity but could be
caused by the defect in the nuclear export of this protein. If
the nuclear export of activated PRAK is truly required for
the inhibition of Ras signaling, the exported PRAK should
have a different function in comparison with the cytoplasmic
PRAK. The majority of MAPKAPK2 was detected in nucleus
and translocated into cytosol upon cellular stress (Ben-Levy
et al., 1998a; Engel et al., 1998). Because of the similarity of
these two kinases in their biochemical properties, whether
the MAPKAPK2 and PRAK molecules had the same func-
tion after translocation into cytosol awaits further investiga-
tion.
The family of downstream kinases of MAP kinases can be
divided into several groups (Stokoe et al., 1992; Ludwig et al.,
1996; Fukunaga and Hunter, 1997; Waskiewicz et al., 1997;
Deak et al., 1998; New et al., 1999). It was proposed that
PRAK represents a subgroup of this family because it only
has 20–30% sequence identity with kinases in the family
(New et al., 1998). However, comparative studies did not
find a difference between PRAK and the intensively studied
MAPKAPK2 (New et al., 1998; Tanoue et al., 2001). The study
described here revealed that the subcellular location of
PRAK is different from MAPKAPK2, thus providing a di-
rection for studying the difference between PRAK and MAP-
KAPK2. Therefore, the constant shuttling between the nu-
cleus and the cytoplasm is another important feature of
PRAK and may be essential in understanding the biological
function of PRAK.
Figure 8. Regulation of subcellular location and translocation of
PRAK by p38 and p38. See text for details.
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